Presentation is loading. Please wait.

Presentation is loading. Please wait.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

Published byInger Klausen Modified over 4 years ago

Similar presentations

Presentation on theme: "Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH."— Presentation transcript:

1 Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial.
Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Full analysis set. A and B: A1C. C and D: FPG. Estimated treatment differences (ETDs; degludec – glargine U100) for change in A1C after 32 weeks of treatment are derived from a mixed model for repeated measures with an unstructured covariance matrix including sex, antidiabetic therapy at screening, visit and dosing time as fixed effects, and age and baseline A1C as covariates. FPG, fasting plasma glucose. Louis Chaykin et al. Clin Diabetes 2019;37:73-81 ©2019 by American Diabetes Association

Download ppt "Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH."

Similar presentations

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.
Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes.

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes.
GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.
1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.

1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.
A Diabetes Outcome Progression Trial

A Diabetes Outcome Progression Trial
New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.

New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.
 SC Guidelines for Diabetes Care 2011. Screening for Diagnosis of Diabetes To test for diabetes or to assess risk of future diabetes, either A1C, Fasting.

 SC Guidelines for Diabetes Care Screening for Diagnosis of Diabetes To test for diabetes or to assess risk of future diabetes, either A1C, Fasting.
Tresiba- insulin degludec

Tresiba- insulin degludec
GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.
Featured Article: Wayne H.-H. Sheu, Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Arpana Mirza, Barry J. Goldstein, Keith D. Kaufman, and Samuel S. Engel.

Featured Article: Wayne H.-H. Sheu, Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Arpana Mirza, Barry J. Goldstein, Keith D. Kaufman, and Samuel S. Engel.
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.

Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.
Key publication slides

Key publication slides
Mastery of Medicine in Diabetes Management Video Roundtable

Mastery of Medicine in Diabetes Management Video Roundtable
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive.

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive.
Placebo Metformin ***p < vs placebo

Placebo Metformin ***p < vs placebo
From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.

From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.
Special Consideration in Insulin Therapy

Special Consideration in Insulin Therapy
The Next Generation of Basal Insulins

The Next Generation of Basal Insulins
Modern Strategies for Basal Insulin Use in T2D

Modern Strategies for Basal Insulin Use in T2D

Similar presentations

Ads by Google